Sanofi Canada announced that Mozobil™ (plerixafor), a new treatment for the mobilization of stem cells in patients with non-Hodgkin's Lymphoma (NHL) and multiple myeloma (MM), is now available on the Canadian market. Mozobil™ is the first in a new class of haematopoietic stem cell mobilising agents that reversibly blocks the CXCR4-SDF-1a interaction in the bone marrow. Mozobil™ is intended to be used in combination with granulocyte-colony stimulating factor (G-CSF) for the collection of stem cells in order to be able to perform an autologous transplantation in patients with NHL and MM. Mozobil™ was granted market authorization by Health Canada in December, 2011.

"Mozobil™ is an important advancement in the treatment of patients with certain types of blood cancer who require stem cell transplant," said Dr. Ronan Foley, Haematologist and President of the Canadian Blood and Marrow Transplant Group representing 23 transplant centres across Canada. "Advancement such as Mozobil™ that can provide patients with hope for remission or a cure is very important when you are dealing with such a difficult illness."

To read complete release click here

For more information :